Ligutom, Marilyn .

HRN: 14-67-03  Sex: Female

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/10/2025
CEFUROXIME 1.5GM (VIAL)
10/11/2025
10/11/2025
IV
1500mg
On Call To OR
For TAHBSO
Checking Initial Appropriateness 
10/10/2025
CIPROFLOXACIN 500MG (TAB)
10/10/2025
10/16/2025
ORAL
500mg
Every 8 Hours
For TAHBSO
Checking Initial Appropriateness 
10/10/2025
METRONIDAZOLE 500MG (TAB)
10/10/2025
10/16/2025
ORAL
500mg
Every 8 Hours
For TAHBSO
Checking Initial Appropriateness 
10/11/2025
CEFUROXIME 1.5GM (VIAL)
10/11/2025
10/12/2025
IVT
1.5g
Q8
S/p TAHBSO Enterolysis
Remove - Pending Acceptance
10/13/2025
MUPIROCIN 2%, 15G (TUBE)
10/13/2025
10/20/2025
TOPICAL
15g
OD
S/P Tahbso
Remove - Pending Acceptance

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: